Portola Pharma (PTLA) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update
February 26, 2016 5:00 AM ESTSOUTH SAN FRANCISCO, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today provided a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2015.
During the fourth quarter of 2015, we executed on several milestones that we expect will make 2016 a year of unprecedented progress. We plan to commercially launch andexanet alfa and report pivotal Phase 3 results from our APEX study that, if positive, will support the global approval of betrixaban, said Bill Lis, chief executive officer of Portola. Both have the potential to benefit the... More
